Results 31 to 40 of about 4,104 (188)

Cushing’s disease: Does low-dose pasireotide offer a comparable efficacy and safety to high-dose?

Endocrinology, Diabetes & Metabolism Case Reports, 2021
Whilst literature is expanding on pasireotide use in the management of Cushing’s disease (CD), there is still currently much unknown about long-term and low-dose pasireotide use in CD. We present a 60-year-old female with residual CD after transphenoidal
Mimi Wong, Usman H Malabu, Ipeson Korah, YongMong Tan   +3 more
doaj   +1 more source

Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly

Clinical Endocrinology, 2023
Hyperintensity signal in T2‐weighted magnetic resonance imaging (MRI) has been related to better therapeutic response during pasireotide treatment in acromegaly.
Sabina Ruiz, J. Gil, B. Biagetti, E. Venegas, R. Cámara, Rogelio Garcia-Centeno, M. Gálvez, A. Picó, Silvia Maraver, I. Gonzalez, P. Abellán, P. Trincado, Mayte Herrera, P. Olvera, G. Xifra, I. Bernabéu, Guillermo Serra-Soler, S. Azriel, Lourdes García, D. Carvalho, Mireia Jordà, E. Valassi, J. Puig, Manel Puig-Domingo   +23 more
semanticscholar   +1 more source

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.

PLoS ONE, 2019
BackgroundSignaling through mTOR and somatostatin pathway is implicated in thyroid cancer development.MethodWe evaluated everolimus, an mTOR inhibitor and pasireotide, a multi receptor somatostatin analogue as potential therapy of thyroid cancer focusing
Taofeek K Owonikoko, Guojing Zhang, Shenila B Lallani, Zhengjia Chen, Deborah E Martinson, Fadlo R Khuri, Sagar Lonial, Adam Marcus, Shi-Yong Sun   +8 more
doaj   +1 more source

Pasireotide in the Personalized Treatment of Acromegaly

Frontiers in Endocrinology, 2021
The delay in controlling the disease in patients who do not respond to first-line treatment with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified in years, as every modification in the medical therapy requires some
Manel Puig-Domingo, Ignacio Bernabéu, Antonio Picó, Betina Biagetti, Joan Gil, Cristina Alvarez-Escolá, Mireia Jordà, Montserrat Marques-Pamies, Berta Soldevila, María-Angeles Gálvez, Rosa Cámara, Javier Aller, Cristina Lamas, Mónica Marazuela   +13 more
doaj   +1 more source

Antiparallel β‐Sheet as a Key Motif of Amyloid‐β Inhibitor Designed via Topological Peptide Reprogramming

Angewandte Chemie, Volume 137, Issue 28, July 7, 2025.
Targeting Amyloid‐β (Aβ) aggregation requires a peptide‐based approach that accounts for the structural heterogeneity of Aβ. Here, we employ topological reprogramming via disulfide bonds to stabilize antiparallel β‐sheets within the dimeric peptide.
Dongjoon Im, Ye Eun Lee, Gyusub Yoon, William A. Goddard III, Tae Su Choi, Hugh I. Kim   +5 more
wiley   +2 more sources

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Frontiers in Endocrinology, 2019
Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (
Maria Fleseriu, Chioma Iweha, Luiz Salgado, Tania Longo Mazzuco, Federico Campigotto, Ricardo Maamari, Padiporn Limumpornpetch   +6 more
doaj   +1 more source

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment

Clinical Case Reports, 2020
Pasireotide improves hypercortisolemia and induces hyperglycemia via somatostatin receptor type‐5 stimulation. GLP‐1RA and SGLT2 inhibitor potentially help regulate hyperglycemia in patients with Cushing's disease, especially after pasireotide ...
Masato Shikata, Kenji Ashida, Yuka Goto, Ayako Nagayama, Shimpei Iwata, Mamiko Yano, Nao Hasuzawa, Kento Hara, Kazutoshi Mawatari, Kiyohiko Sakata, Munehisa Tsuruta, Nobuhiko Wada, Masatoshi Nomura   +12 more
doaj   +1 more source

Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia

Endocrinology, Diabetes & Metabolism Case Reports, 2017
Long-acting pasireotide is an effective treatment option for acromegaly, but it is associated with hyperglycemia, which could impact its use in patients with diabetes.
Murray B Gordon, Kellie L Spiller
doaj   +1 more source

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Frontiers in Endocrinology, 2020
Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I).
Mônica Gadelha, Marie Bex, Annamaria Colao, Elier Mitsael Pedroza García, Catalina Poiana, Marisela Jimenez-Sanchez, Serkan Yener, Rishav Mukherjee, Amy Bartalotta, Ricardo Maamari, Gérald Raverot   +10 more
doaj   +1 more source

Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up

Journal of Endocrinological Investigation
Pasireotide LAR (PAS-LAR) was released in Italy in 2017 to treat acromegaly patients resistant to SRLs (Somatostatin Receptors Ligands). The long-term follow-up data of PAS-LAR therapy in Italy are limited.
C. Urbani, F. Dassie, B. Zampetti, R. Mioni, P. Maffei, R. Cozzi, F. Bogazzi   +6 more
semanticscholar   +1 more source